small molecule

FOCINVEZ

FOSAPREPITANT DIMEGLUMINE

Loss of exclusivityJanuary 2039latest FDA-listed patent expiry
CompanySTERISCIENCE PTE LTD

Drug detail

Brand nameFOCINVEZ
Active ingredientFOSAPREPITANT DIMEGLUMINE
StrengthEQ 150MG BASE/50ML (EQ 3MG BASE/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalAugust 2023
Marketing statusRX

Listed patents

PatentExpiresType
12042504January 2039product
11065265January 2039product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

FOCINVEZ patent cliff — loss of exclusivity January 2039 | CliffBio